Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 735 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Data Shows Women Are Not Getting Access To An Important Part... July 30, 2021 Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto August 20, 2020 ESMO Gynaecological Cancers Congress 2023 February 10, 2023 seven Interesting Facts about Malignant tumors Boy Between the sheets July 20, 2023 Load more HOT NEWS 10 Ways to Brave Cancer Treatment: Tips from a Survivor ESMO Sarcoma and Rare Cancers Congress 2024 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... 2022 ASCO Annual Meeting Research Round Up: New Research in Head...
